Incidence and prevalence of NMOSD in Australia and New Zealand
Author(s)
Bukhari, Wajih
Prain, Kerri M
Waters, Patrick
Woodhall, Mark
O'Gorman, Cullen M
Clarke, Laura
Silvestrini, Roger A
Bundell, Christine S
Abernethy, David
Bhuta, Sandeep
Blum, Stefan
Boggild, Mike
Boundy, Karyn
Brew, Bruce J
Brown, Matthew
Brownlee, Wallace J
Butzkueven, Helmut
Carroll, William M
Chen, Celia
Coulthard, Alan
Dale, Russell C
Das, Chandi
Dear, Keith
Fabis-Pedrini, Marzena J
Fulcher, David
Gillis, David
Hawke, Simon
Heard, Robert
Henderson, Andrew PD
Heshmat, Saman
Hodgkinson, Suzanne
Jimenez-Sanchez, Sofia
Killpatrick, Trevor
King, John
Kneebone, Christopher
Kornberg, Andrew J
Lechner-Scott, Jeannette
Lin, Ming-Wei
Lynch, Christpher
Macdonell, Richard
Mason, Deborah F
McCombe, Pamela A
Pender, Michael P
Pereira, Jennifer A
Pollard, John D
Reddel, Stephen W
Shaw, Cameron
Spies, Judith
Stankovich, James
Sutton, Ian
Vucic, Steve
Walsh, Michael
Wong, Richard C
Yiu, Eppie M
Barnett, Michael H
Kermode, Allan G
Marriott, Mark P
Parratt, John DE
Slee, Mark
Taylor, Bruce V
Willoughby, Ernest
Wilson, Robert J
Vincent, Angela
Broadley, Simon A
Griffith University Author(s)
Year published
2017
Metadata
Show full item recordAbstract
Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry.
Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established.
Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for ...
View more >Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture–recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48%) cases referred. Capture–recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.
View less >
View more >Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture–recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48%) cases referred. Capture–recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.
View less >
Journal Title
Journal of Neurology, Neurosurgery and Psychiatry
Volume
88
Issue
8
Subject
Biomedical and clinical sciences
Psychology